

## Assoc. Prof. Nebi Serkan DEMİRCİ

### Personal Information

**Email:** nebiserkan.demirci@iuc.edu.tr

**Web:** <http://avesis.istanbulc.edu.tr/4321/>

### Research Areas

Health Sciences

### Academic Titles / Tasks

Associate Professor, İstanbul University-Cerrahpaşa, Cerrahpasa Faculty Of Medicine, Department Of Internal Medicine, 2020 - Continues

### Articles Published in Journals That Entered SCI, SSCI and AHCI Indexes

- I. **Use of volumetric CT scanning to predict tumor staging and survival in pancreatic cancer patients that are to be administered curative resection**  
ŞENGÜL SAMANCI N., ÇELİK E., BAĞCILAR Ö., TUTAR O., SAMANCI C., VELİDEDEOĞLU M., YASSA A. E. , DEMİRCİ N. S. , DEMİRELLİ F. H.  
JOURNAL OF SURGICAL ONCOLOGY, 2021 (Journal Indexed in SCI)
- II. **Independent prognostic value of inflammation in metastatic pancreatic cancer.**  
Oksuzoglu B., Esin E., Koksoy E. B. , Demirci N. S. , Sendur M. A. N. , Dede I., Sezer A., Karci E., Yildirim N., Yalcin B., et al.  
JOURNAL OF CLINICAL ONCOLOGY, vol.36, no.15, 2018 (Journal Indexed in SCI)
- III. **Preoperative platelet-to-lymphocyte ratio is a predictor of prognosis in patients with ampullary carcinoma**  
Demirci N. S. , Ozdemir N. Y. , Erdem G. U. , Bozkaya Y., Yazici O., Zengin N.  
BRATISLAVA MEDICAL JOURNAL-BRATISLAVSKE LEKARSKE LISTY, vol.119, no.3, pp.180-186, 2018 (Journal Indexed in SCI)
- IV. **Queries for the article entitled "Predictors for extensive nodal involvement in breast cancer patients with axillary lymph node metastases"**  
Erdem G. U. , Sahin S., Karatas F., Aytekin A., Demirci N. S. , Yazilias D.  
BREAST, vol.36, pp.104-105, 2017 (Journal Indexed in SCI)
- V. **Is plasma caveolin-1 level a prognostic biomarker in metastatic pancreatic cancer?**  
Demirci N. S. , Dogan M., Erdem G. U. , Kacar S., Turhan T., KILIÇKAP S., Cigirgan L. C. , Kayacetin E., Bozkaya Y., Zengin N.  
SAUDI JOURNAL OF GASTROENTEROLOGY, vol.23, no.3, pp.183-189, 2017 (Journal Indexed in SCI)
- VI. **Comparative study of receptor discordance between primary and corresponding metastatic lesions in breast cancer.**  
Erdem G. U. , Altundag K., Ozdemir N. Y. , Sahin S., Demirci N. S. , Karatas F., Bozkaya Y., Aytekin A., Tasdemir V., Aslan A. C. , et al.  
Journal of B.U.ON. : official journal of the Balkan Union of Oncology, vol.22, pp.365-376, 2017 (Journal Indexed in SCI Expanded)

- VII. **Modified docetaxel, cisplatin and fluorouracil therapy as the first-line treatment for patients with recurrent/metastatic squamous cell carcinoma of the head and neck cancer: a retrospective study**  
Demirci N. S. , AKSOY S., Ozdemir N. Y. , Erdem G. U. , Ozelik M., Tanrikulu E., Eren T., Bozkaya Y., Sahin S., Basol F., et al.  
CURRENT MEDICAL RESEARCH AND OPINION, vol.33, no.3, pp.401-407, 2017 (Journal Indexed in SCI)
- VIII. **Comparison of clinicopathological and prognostic characteristics in patients with mucinous carcinoma and signet ring cell carcinoma of the stomach**  
Bozkaya Y., Erdem G. U. , Ozdemir N. Y. , Demirci N. S. , Hocasade C., Yazici O., Zengin N.  
CURRENT MEDICAL RESEARCH AND OPINION, vol.33, no.1, pp.109-116, 2017 (Journal Indexed in SCI)
- IX. **The efficacy of modified docetaxel-cisplatin-5-fluorouracil regimen as first-line treatment in patients with alpha-fetoprotein producing gastric carcinoma**  
Bozkaya Y., Dogan M., Yazici O., Erdem G. U. , Demirci N. S. , Zengin N.  
BOSNIAN JOURNAL OF BASIC MEDICAL SCIENCES, vol.17, no.2, pp.138-143, 2017 (Journal Indexed in SCI)
- X. **Prognostic Effect of Symptomatic and Asymptomatic Venous Thromboembolism in Patients with Gastric Cancer**  
Bozkaya Y., Ozdemir N., Demirci N. S. , Erdem G. U. , Yazici O., Arslan S., Zengin N.  
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.27, no.2, pp.100-109, 2017 (Journal Indexed in SCI)
- XI. **The clinical and pathological features affecting the time of relapse in patients with early stage colorectal cancer**  
Yazilitas D., Ozdemir N., Yazici O., Hocasade C., Demirci N. S. , Zengin N.  
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, vol.12, no.4, pp.1257-1260, 2016 (Journal Indexed in SCI)
- XII. **Is second-line systemic chemotherapy beneficial in patients with non-small cell lung cancer (NSCLC)? A multicenter data evaluation by the Anatolian Society of Medical Oncology**  
Odabas H., Ulas A., Aydin K., İNANÇ M., Aksoy A., Yazilitas D., Turkeli M., Yuksel S., Inal A., Ekinci A. S. , et al.  
TUMOR BIOLOGY, vol.36, no.12, pp.9641-9648, 2015 (Journal Indexed in SCI)
- XIII. **A rare case: Hallucination associated with pazopanib**  
Demirci N. S. , Erdem G. U. , Dogan M., Ozdemir N. Y. , Zengin N.  
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, vol.11, no.4, pp.961-962, 2015 (Journal Indexed in SCI)
- XIV. **Rectal Cancer With Metastasis to the Face**  
Yazilitas D., Dogan M., Ileri A. B. , Ozdemir N., Demirci N. S. , Zengin N.  
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.25, no.2, pp.145-147, 2015 (Journal Indexed in SCI)
- XV. **Can targeted programmed death-1 antibody be a new treatment approach in breast cancer.**  
Sendur M. A. N. , Aksoy S., Demirci S., Ozdemir N. Y. , Zengin N., Altundag K.  
Journal of B.U.ON. : official journal of the Balkan Union of Oncology, vol.19, pp.584, 2014 (Journal Indexed in SCI Expanded)
- XVI. **IS SECOND LINE SYSTEMIC CHEMOTHERAPY BENEFICIAL IN PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC)? : A MULTICENTER DATA EVALUATION OF ANATOLIAN SOCIETY OF MEDICAL ONCOLOGY (ASMO)**  
Odabas H., Ulas A., Aydin K., İNANÇ M., Aksoy A., Yazilitas D., Turkeli M., Yuksel S., Inal A., Ekinci A. S. , et al.  
JOURNAL OF THORACIC ONCOLOGY, vol.8, 2013 (Journal Indexed in SCI)

## Articles Published in Other Journals

- I. **The Determinants of Profitability in Manufacturing Industry Sector: Panel Data Analysis with CBRT Sectoral Balance Sheets (1996-2015)**  
Demirci N. S.  
EGE ACADEMIC REVIEW, vol.17, no.3, pp.381-393, 2017 (Journal Indexed in ESCI)

## Refereed Congress / Symposium Publications in Proceedings

- I. **Modified epirubicin and oxaliplatin plus capecitabine (EOX) Regimen as second-line therapy after failure of modified docetaxel and cisplatin plus fluorouracil (DCF) regimen in advanced gastric cancer**  
Bozkaya Y., Yazici O., Ozdemir N., Erdem G. U. , Demirci N. S. , Zengin N.  
42nd European-Society-for-Medical-Oncology Congress (ESMO), Madrid, Spain, 8 - 12 September 2017, vol.28
- II. **Plasma caveolin-1 level: A prognostic marker for pancreatic cancer.**  
Demirci N. S. , Dogan M., Erdem G. U. , Kacar S., Turhan T., Yilmaz F. M. , Kilickap S., Cigirgan L. C. , Kayacetin E., Zengin N.  
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 3 - 07 June 2016, vol.34
- III. **Modified docetaxel, cisplatin and fluorouracil therapy as a first-line treatment for patients with recurrent/metastatic squamous cell carcinoma of the head and neck cancer: a retrospective study.**  
Demirci N. S. , Aksoy S., Ozdemir N., Babacan T., Erdem G. U. , Bozkaya Y., Zengin N., Gullu I. H.  
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 3 - 07 June 2016, vol.34
- IV. **Clinicopathologic analysis and prognostic factors for survival in early stage patients with ampullary carcinoma.**  
Ozdemir N., Demirci N. S. , Yuksel S., Erdem G. U. , Odabas H., Boruban M. C. , Hacibekiroglu I., Karaagac M., Ucar M., Ozturk B., et al.  
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 3 - 07 June 2016, vol.34
- V. **Comparative study of receptor expression diversity between primary and recurrent lesions in patients with metastatic breast cancer.**  
Erdem G. U. , Ozdemir N., Sahin S., Demirci N. S. , Karatas F., Bozkaya Y., Aytakin A., Sever A. R. , Zengin N., Altundag M. K.  
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 3 - 07 June 2016, vol.34
- VI. **Effect of adding taxane to platin-5-fluorouracil combination on survival in elderly patients with advanced gastric cancer: A retrospective-multicenter study.**  
Gunaldi M., Kose F., Demirci N. S. , Gundur S., Ozdemir N., Kocoglu H., OKUTURLAR Y., Sedef A. M. , Erdem D., Goksu S. S. , et al.  
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 3 - 07 June 2016, vol.34
- VII. **The importance of thiol/disulphide homeostasis in patients with advanced gastric cancer (AGC) receiving modified docetaxel and cisplatin plus fluorouracil (mDCF) regimen**  
Yazici O., Ozdemir N., EREL Ö., Demirci N. S. , AKSOY S., ŞENDUR M. A. N. , Dogan M., Yazililas D., Erdem G. U. , Neselioglu S., et al.  
European Cancer Congress, Vienna, Austria, 01 January 2015, vol.51
- VIII. **The importance of thiol/disulphide homeostasis in patients with advanced colorectal cancer receiving modified fluorouracil and leucovorin plus oxaliplatin (mFOLFOX) regimen**  
Yazici O., Dogan M., EREL Ö., Bozkaya Y., Ozdemir N., Demirci N. S. , NEŞELİOĞLU S., AKSOY S., Zengin N.  
European Cancer Congress, Vienna, Austria, 01 January 2015, vol.51
- IX. **Operated and early stage ampulla vateri tumours: Prognostic assessment**  
Yildirim N., Mulazimoglu E., Yuksel S., Demirci N. S. , Erdem G. U. , Odabas H., Ozturk B., Hacibekiroglu I., Yazici O., Karaagac M., et al.  
European Cancer Congress, Vienna, Austria, 01 January 2015, vol.51
- X. **The effect of body mass index on prognosis and survival of ER(-) and PR(+) nonmetastatic breast cancer patients: Single institute experience.**  
Dogan M., Erdem G. U. , Demirci N. S. , Zengin N.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, United States Of America, 29 May - 02 June 2015, vol.33

## Citations

Total Citations (WOS):81

h-index (WOS):6